BACKGROUND: We have previously shown that the HIV protease inhibitor lopinavir has selective toxicity against human papillomavirus (HPV)-positive cervical carcinoma cells via an unknown mechanism. METHODS: SiHa cervical carcinoma cells were stably transfected with the proteasome sensor vector pZsProSensor-1 to confirm lopinavir inhibits the proteasome in these cells. The Panorama Xpress profiler 725 antibody array was then used to analyse specific changes in protein expression in lopinavir-treated versus control untreated SiHa cells followed by PCR and western blotting. Colorimetric growth assays of lopinavir-treated E6/E7 immortalised versus control human keratinocytes were performed. Targeted small interfering RNA gene silencing followed by growth assay comparison of lopinavir-treated/untreated SiHa cells was also used. RESULTS: Lopinavir induced an increase in the fluorescence of pZsProSensor-1 transfected SiHa cells, indicative of proteasomal inhibition. Ribonuclease L (RNASEL) protein was shown to be up-regulated in lopinavir-treated SiHa cells, which was confirmed by PCR and western blot. Targeted silencing of RNASEL reduced the sensitivity of SiHa cells to lopinavir. Selective toxicity against E6/E7 immortalised keratinocytes versus control cells was also seen with lopinavir and was associated with up-regulated RNASEL expression. CONCLUSIONS: These data are consistent with the toxicity of lopinavir against HPV-positive cervical carcinoma cells being related to its ability to block viral proteasome activation and induce an up-regulation of the antiviral protein RNASEL. This is supported by the drug's selective toxicity and up-regulation of RNASEL in E6/E7 immortalised keratinocytes combined with the increased resistance to lopinavir observed in SiHa cells following silencing of RNASEL gene expression.
BACKGROUND: We have previously shown that the HIV protease inhibitor lopinavir has selective toxicity against humanpapillomavirus (HPV)-positive cervical carcinoma cells via an unknown mechanism. METHODS: SiHa cervical carcinoma cells were stably transfected with the proteasome sensor vector pZsProSensor-1 to confirm lopinavir inhibits the proteasome in these cells. The Panorama Xpress profiler 725 antibody array was then used to analyse specific changes in protein expression in lopinavir-treated versus control untreated SiHa cells followed by PCR and western blotting. Colorimetric growth assays of lopinavir-treated E6/E7 immortalised versus control human keratinocytes were performed. Targeted small interfering RNA gene silencing followed by growth assay comparison of lopinavir-treated/untreated SiHa cells was also used. RESULTS:Lopinavir induced an increase in the fluorescence of pZsProSensor-1 transfected SiHa cells, indicative of proteasomal inhibition. Ribonuclease L (RNASEL) protein was shown to be up-regulated in lopinavir-treated SiHa cells, which was confirmed by PCR and western blot. Targeted silencing of RNASEL reduced the sensitivity of SiHa cells to lopinavir. Selective toxicity against E6/E7 immortalised keratinocytes versus control cells was also seen with lopinavir and was associated with up-regulated RNASEL expression. CONCLUSIONS: These data are consistent with the toxicity of lopinavir against HPV-positive cervical carcinoma cells being related to its ability to block viral proteasome activation and induce an up-regulation of the antiviral protein RNASEL. This is supported by the drug's selective toxicity and up-regulation of RNASEL in E6/E7 immortalised keratinocytes combined with the increased resistance to lopinavir observed in SiHa cells following silencing of RNASEL gene expression.
Authors: Cecile D Lahiri; Katherine B Dugan; Xianhong Xie; Laura Reimers; Robert D Burk; Kathryn Anastos; Leslie Stewart Massad; Isam-Eldin Eltoum; Xiaonan Xue; Gypsyamber DʼSouza; Lisa Flowers; Joel M Palefsky; Lisa Rahangdale; Howard D Strickler; Ighovwerha Ofotokun Journal: J Acquir Immune Defic Syndr Date: 2015-10-01 Impact factor: 3.731
Authors: Peter L Stern; Sjoerd H van der Burg; Ian N Hampson; Thomas R Broker; Alison Fiander; Charles J Lacey; Henry C Kitchener; Mark H Einstein Journal: Vaccine Date: 2012-11-20 Impact factor: 3.641
Authors: Julie Dyall; Robin Gross; Jason Kindrachuk; Reed F Johnson; Gene G Olinger; Lisa E Hensley; Matthew B Frieman; Peter B Jahrling Journal: Drugs Date: 2017-12 Impact factor: 9.546
Authors: Korbinian Bösl; Aleksandr Ianevski; Thoa T Than; Petter I Andersen; Suvi Kuivanen; Mona Teppor; Eva Zusinaite; Uga Dumpis; Astra Vitkauskiene; Rebecca J Cox; Hannimari Kallio-Kokko; Anders Bergqvist; Tanel Tenson; Andres Merits; Valentyn Oksenych; Magnar Bjørås; Marit W Anthonsen; David Shum; Mari Kaarbø; Olli Vapalahti; Marc P Windisch; Giulio Superti-Furga; Berend Snijder; Denis Kainov; Richard K Kandasamy Journal: Front Immunol Date: 2019-10-04 Impact factor: 7.561
Authors: Lynne Hampson; Innocent O Maranga; Millicent S Masinde; Anthony W Oliver; Gavin Batman; Xiaotong He; Minaxi Desai; Parmenas M Okemwa; Helen Stringfellow; Pierre Martin-Hirsch; Alex M Mwaniki; Peter Gichangi; Ian N Hampson Journal: PLoS One Date: 2016-01-29 Impact factor: 3.240